T reatment of patients with acute ischemic stroke (AIS) is aimed at reopening occluded arteries and reestablishment of intracranial perfusion. Determining pivotal characteristics about the occluding thrombus using available imaging has the potential to improve patient's diagnostics and prognostics.
In stroke management, the thrombus is commonly regarded as a cork where the artery is completely occluded. However, permeability of thrombi, which allows (blood) flow through the thrombus, is a well-known characteristic in preclinical studies. [1] [2] [3] Moreover, a thrombus may only partly occlude an artery, allowing for residual blood flow. 4 Yet, the permeability of thrombi occluding intracranial arteries has not been assessed in patients with AIS. It is expected that the passage of residual flow through a thrombus has a positive effect on outcome of patients with AIS because it may enhance the oxygenation of the brain tissue distal to the occluded artery. It may also result in more effective activation of recombinant tissue-type plasminogen, potentially improving thrombus dissolution success. 5 Moreover, thrombus porosity may influence its mechanical properties and improve intra-arterial treatment (IAT) success. 6 With the advent of IAT, computed tomographic angiography (CTA) has become an integral part of the radiological workup of patients suspected of AIS for detecting intracranial large vessel occlusions. 7 This has created an opportunity to study thrombus permeability based on joint analysis of CTA and noncontrast CT (NCCT) data. 4 We hypothesize that the level of contrast penetration in a thrombus can be assessed by determining attenuation increase on CTA and void fraction using combination of NCCT and CTA, and that it is associated with outcome.
Materials and Methods

Patient Selection
Patients were selected from the Multicenter Randomized Clinical trial of Endovascular treatment of acute ischemic stroke in the Netherlands (MR CLEAN) cohort. 7, 8 Inclusion criteria for this substudy were thin-slice NCCT and CTA (<2.5 mm) performed on the same scanner within 30 minutes. Clinical outcome such as modified Rankin Scale (mRS), modified Arterial Occlusive Lesion (mAOL) score, Thrombolysis in Cerebral Infarction perfusion scale (TICI) score, and final infarct volume (FIV), 9 and baseline clinical characteristics (such as age, sex, National Institutes of Health Stroke Scale [NIHSS] score, time from onset to intravenous [IV] recombinant tissue-type plasminogen activator [r-tPA] treatment, time from onset to groin puncture, occlusion site, and atrial fibrillation) were collected during the execution of the trial. Of 248 consecutive patients with thin-slice NCCT and CTA, 10 were excluded because the time between NCCT and CTA imaging exceeded 30 minutes, 3 because CTA was performed before NCCT imaging, 3 because CTA and NCCT were performed on a different scanner, 39 because of imaging quality limitations, including movement artifacts (25) , noisy NCCT image (10) , incomplete region of interest (3), and CTA triggered too early or too late (1) . Of the 193 remaining patients, imaging data of 9 patients were used for manual thrombus intensity signal measurement training. The remaining 184 patients were included in this study ( Figure  1 ). The MR CLEAN trial and imaging substudies have been approved by a central medical ethics committee and the research boards of all participating centers and written informed consent was acquired from all patients or legal representatives.
Thrombus Attenuation Measurements
In this study, we performed a common thrombus attenuation measurement as described previously. 10 In short, CTA images were automatically aligned with NCCT images using a rigid registration method. 11 The quality of the registration was assessed by visual inspection. If the registration was suboptimal, a correction was performed (by E.M.M.S.) using manual rigid registration tools 12 before the attenuation assessment was performed. Subsequently, 3 spherical regions of interest with a radius of 1 mm were used to measure the attenuation ρ within the thrombus and similarly in the corresponding contralateral vessel. The measurements were performed by 8 observers: 3 experts (C.B.M., A.J.Y., and L.F.B.) and 5 trained observers (C.W., K.N., E.M.M.S., M.D.B., and K.M.T.). The average of all measurements was used as the mean attenuation for thrombus (ρ Thrombus ) and contralateral artery (ρ Artery ). Note that this approach neglects possible thrombus heterogeneity. The observers only had access to the coregistered baseline NCCT and CTA images during the measurement, and they were blinded toward the measured attenuation and all clinical data.
Perviousness Estimates
Because the quantification of permeability requires dynamic imaging, it cannot be measured in the snapshot of CTA and NCCT images. Instead, we propose 2 methods to gauge the thrombus permeability by assessing the amount of penetrated contrast agent in the thrombus and refer to thrombus perviousness rather than thrombus permeability in the remainder of the text. We introduce (1) the CTA thrombus attenuation increase (Δ), which is the increase of ρ Thrombus in the thrombus on CTA compared with NCCT; ∆=ρ Thrombus CTA −ρ Thrombus NCCT and (2) the thrombus void fraction (ε). The void fraction is a measure that represents the ratio of the thrombus void volume over the total thrombus volume. It is possible to estimate the void fraction by measuring attenuation coefficients in the thrombus and contralateral artery in NCCT and CTA images and compute the ratio of the attenuation increase Δ in the thrombus and Δ c on the contralateral side: ε=∆/∆ c . The calculation of the thrombus void fraction is further detailed in the Method I in the onlineonly Data Supplement. 
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Statistical Analysis
Favorable outcome, defined as mRS score of ≤2 at 90 days after stroke onset, was used as the primary outcome measure. Secondary outcome measures were the score on the mRS, early recanalization (mAOL≥2) and FIV. Differences in ∆ and ε for favorable and unfavorable outcome and all dichotomized baseline characteristics were compared using unpaired t-tests; the Student's for normally distributed determinants and the Mann-Whitney test and Kolmogorov-Smirnov otherwise. The associations of ∆ and ε with ordinal mRS were investigated using a 1-way ANOVA for normally distributed continuous variables and Kruskal-Wallis ANOVA otherwise. For normally distributed continuous determinants, the Pearson correlation coefficient was calculated and Spearman correlation coefficient otherwise. Strength of the association of ∆ and ε with favorable outcome was assessed using the Fisher exact test of proportions for categorical data. Two-graph receiver operating characteristic analysis was performed to determine the optimal threshold values for ∆ and ε to classify the thrombus as Pervious or Impervious. 13 The cut-off value for this categorization was selected to optimize the sensitivity and specificity parameter estimates. Odds ratios (ORs) were calculated using a univariate general linear model to measure the likelihood of a favorable outcome and recanalization for a pervious thrombus. We also studied prediction of favorable outcome and recanalization per increase of ∆ (1 HU) and ε (10% void fraction) using binary logistic regression analysis.
Associations of ∆ and ε with FIV were studied using linear regression and calculation of the Pearson correlation coefficient for normally distributed determinants and FIV, and Spearman correlation coefficient otherwise; the coefficient of determination R 2 was used to evaluate the fit to the regression.
Confounding Analysis
To address potential confounding effects on the association of perviousness with favorable functional outcome, we determined adjusted OR (aOR) of perviousness using 2 models. First, a model was created including baseline characteristics only (model 1). Second, a model was created that included baseline and follow-up characteristics (model 2). To create the models, all baseline and follow-up characteristics were associated with favorable outcome using a univariate regression. All characteristics with an association with a P<0.10 were included in the multivariate models. Subsequently, the perviousness measures were added to the models allowing the calculation of the aOR. For all models, the R 2 was calculated to assess the goodness of fit.
With the inclusion of strongly related variables, there is a high risk of multicollinearity and singularity. Multicollinearity exists when the correlation between ≥2 characteristics in multivariate models is high. Singularity of model occurs when the correlation between explanatory variables is perfect. Both lead to numeric problems in regression analysis. Multicollinearity and singularity are more common in models that are composed of small groups. To tackle this issue, variables showing multicollinearity or variables with <10 patients were regrouped.
Moreover, the effect modification of the relation of ∆ and ε with favorable outcome was assessed for the baseline characteristics and recanalization status (TICI, mAOL, and fully recanalized at 24 hours). Using linear regression models, perviousness was associated with functional outcome and subsequently each baseline characteristic that was significantly associated with functional outcome and perviousness. Significant effect modification was defined as a change of the perviousness OR for favorable outcome with >10%. 14 Significance level was set to a P value of ≤0.05. All analyses were performed using IBM SPSS Statistics software, version 21.0 (IBM Corporation, Armonk, NY).
Results
Baseline characteristics are presented in Tables 1 and 2 . Age and time of onset to groin puncture were the only normally distributed parameters with an average of 66 (±12) years and 257 (±63) minutes. One hundred thirteen (61.4%) patients were male. The median attenuation increase on CTA was 9.7 (interquartile range [IQR], 1.8-18.7) HU and the median void fraction was 5.0 (IQR, 1.1-12.8) %. The registration was considered accurate in the majority of cases (n=164; 89%). In 20 cases (11%), additional manual adjustment was performed for an optimal registration.
Primary Outcome Measure
Both ∆ and ε were statistically significantly different between the populations with favorable and unfavorable outcome. The median thrombus intensity increase ∆ was 7.6 (IQR, 0.30-17.4) HU for the unfavorable outcome group and 15.3 (IQR, ) HU for the favorable outcome group (P<0.001). The median void fraction ε was 4.2 (IQR, 0.2-10.5) % and 10.2 (IQR, 4.5-17.9) % for the unfavorable and favorable outcome group, respectively (P<0.001). The area under the curves of the receiver operating characteristic curves shown in Figure  2 were 0.67 and 0.69 for Δ and ε, respectively. The optimal thresholds to categorize a thrombus as pervious was 10.9 HU for Δ with a specificity of 64% and a sensitivity of 64%. The optimal threshold for ε was 6.5% with a specificity of 66% and sensitivity of 62%. Therefore, we defined a thrombus as being pervious when the intensity increase on CTA was larger than the threshold of 10.9 HU for Δ, resulting in 44% (81) of the patients having a pervious thrombus. Categorization using the void fraction with a threshold of 6.5% for ε resulted in 42% (77) of the patients having a pervious thrombus. The ORs for favorable outcome of a patient with a pervious thrombus were 3.2 (95% confidence interval [CI], 1.7-6.4) and 3.3 (95% CI, 1.7-6.3) for Δ and ε, respectively. Cross tables and the results of the linear models are displayed in Table 3 . One HU increase in Δ was associated with a 4.4% increase in the relative log odds of a favorable outcome, for ε the association is 93% increase per 10% increase in void fraction.
Secondary Outcome Measures
The Kruskal-Wallis ANOVA test indicated that ∆ and ε are both statistically significantly associated with ordinal mRS (Figure 3 ). The OR for recanalization for a patient with a previous thrombus was 2.5 (95% CI, 1.3-4.8) for Δ and 2.1 (95% CI, 1.1-4.1) for ε. One HU increase in Δ was associated with a 3.4% increase in the odds for recanalization. There is a strong relation of ∆ and ε with FIV (Spearman rho [R 2 ] of 0.33 [0.11] and 0.32 [0.11] for Δ and ε, respectively; P<0.001; Figure 3 ).
Cofounding Analysis
The aORs of perviousness with favorable outcome are presented in the Table 3 . Because of small group size, ICA and ICA-Terminal occlusion were combined. Also patients with an mAOL score of 0 were grouped with mAOL score of 1. After detection of singularities in the functional outcome model, the ordinal TICI score was dichotomized in TICI 0-2a and 2b-3. Continuous NIHSS, ICA/ICA-Terminal occlusion, and all follow-up characteristics (recanalization at 24 hours, mAOL, TICI score, and final infarct core size) were significantly associated with favorable outcome. Because of multicollinearity between TICI score, mAOL, and recanalization at 24 hours, 2 11.75 (1.6 to 21.5) 4.8 (0.5 to 14.9) Δ indicates attenuation increase; ε, void fraction; CTA, computed tomographic angiography; CTP, computed tomography perfusion; IAT, intra-arterial treatment; IQR, interquartile range; mAOL, modified arterial occlusive lesion; mRS, modified Rankin Scale; NIHSS, National Institutes of Health Stroke Scale; and TICI, thrombolysis in cerebral infarction. NIHSS score: 0, no stroke symptoms; 1-4, minor stroke; 5-15, moderate stroke; 16-20, moderate to severe stroke; 21-42, severe stroke. mRS score: 0, no symptoms at all; 1, no significant disability despite symptoms; 2, slight disability; 3, moderate disability; 4, moderately severe disability; 5, severe disability; 6, dead. TICI perfusion scale grade: grade 0, no perfusion; grade 1, penetration with minimal perfusion; grade 2, partial perfusion; grade 2a, only partial filling (<2/3) of the entire vascular territory is visualized; grade 2b, complete filling of all the expected vascular territory is visualized, but the filling is slower than normal; grade 3, complete perfusion. mAOL score: 0, no recanalization of the primary occlusion; 1, incomplete or partial recanalization of the primary occlusion with no distal flow; 2, incomplete or partial recanalization of the primary occlusion with distal flow; 3, complete recanalization of the primary occlusion with distal flow. *P<0.05.
by guest on September 7, 2017 http://stroke.ahajournals.org/
Downloaded from
Stroke
March 2016
different models also including follow-up data were generated: model 2a, including recanalization at 24 hours and excluding TICI and mAOL, and model 2b including TICI and excluding mAOL and recanalization at 24 hours. The associations of all baseline and follow-up characteristics with favorable outcome are presented in the Table I in the online-only Data Supplement. For model 1, the aORs are 2.4 (95% CI, 1.2-4.8) and 2.3 (95% CI, 1.1-4.7) for Δ and ε, respectively. The aORs of perviousness in the models that included follow-up measures were no longer statistically significant. The fits (R 2 values) of the regressions were 0.10, 0.37, and 0.31 for the model 1, model 2a, and model 2b, respectively without perviousness measures. After addition of perviousness, the fit of every model raised or stayed similar. Tables 1 and 2 show all baseline and follow-up characteristics that are statistically significantly associated with the 2 perviousness measures. Occlusion location (for ε) and NIHSS (for both measures) were the only baseline effect modificators of the relation between perviousness and favorable outcome. For the follow-up characteristics, FIV, mAOL, and recanalization at 24 hours were effect modificators. Most noticeably, IAT and IV r-tPA were no confounders in the relation of perviousness and favorable functional outcome indicating that the strong relation between perviousness and favorable outcome is similar for in the MR CLEAN IAT allocation group as well as in the controls.
Discussion
This study shows that thrombus perviousness can be assessed by the simultaneous measurement of thrombus attenuation on NCCT and CTA. We have shown that thrombus perviousness measures are strongly associated with all evaluated outcome measures: favorable outcome, final score on the mRS, recanalization rate, and FIV independently of stroke treatment.
To our knowledge, this is the first study that quantifies CTA thrombus attenuation increase in radiological imaging. Thrombus characteristics, such as clot length, density, and location, are usually determined on NCCT alone. 15, 16 In the past decade, CTA has been used for localization of the thrombus and determining its burden. 17, 18 More recently, similar to this study, residual flow within the thrombus in CTA was qualitatively assessed: contrast attenuation increase in the thrombus was graded using a 3-point scale. 4 Mishra et al 4 found a much lower percentage of patients with thrombus opacification, which may be because of qualitative assessment. Furthermore, patients with residual flow on CTA (defined as a clearly visible increase in contrast attenuation distal to and within the thrombus) were 5× more likely to reperfuse after administration of IV r-tPA. In recent literature, angiographic contrast opacification distal to the occlusion has also been associated with higher odds of recanalization. 19, 20 Frölich et al 20 demonstrated that 4-dimensional (4D) CTA can be used to discriminate anterograde from retrograde flow distal to the thrombus. This anterograde filling could very well be related to the thrombus perviousness measures as presented in this study; however, this association could not be tested because 4D CTA was not available.
Our results support our hypothesis that perviousness of the thrombus is associated with improved outcome and reduced infarct volume. This may be because of better distal tissue oxygenation. The odds for favorable outcome were notably higher than the odds for successful recanalization, which may also be in support of improved brain tissue oxygenation.
The confounding analyses showed that perviousness is an independent predictor of outcome in a multivariate model with baseline parameters only. However, it was not for the models including outcome measures as well. The loss of significance of perviousness is probably because of the strong causal relationship between perviousness and other outcome measures, such as FIV, mAOL, and recanalization at 24 hours. Surprisingly in the MR CLEAN population, IV r-tPA and IAT were not statistically associated with perviousness. This implies that the association of perviousness with outcome is similar in the intra-arterial-treated patients and with the controls for favorable outcome. Measured perviousness was higher for low thrombus attenuation on NCCT, which may reflect that a low-dense thrombus is more porous. However, the low-Spearman value of the association (Table 2) suggests that thrombus density measured on NCCT can only partially explain its perviousness measure. Notably, Δ and ε were lower for ICA occlusions than for thrombi at the M1 and M2. This could be explained by differences in thrombus size. ICA thrombi are generally larger, which could make it more difficult for contrast agent to reach the distal segments of the clot, resulting in a lower overall attenuation increase after contrast administration. Another important factor could be the poor contrast delivery to the clot, which is sometimes seen with ICA occlusions (ie, pseudoocclusion), given the lack of outflow and resultant stagnation of blood. 21 We presented 2 measures for assessing the thrombus perviousness: CTA-based intensity increase Δ and void fraction ε. Both have similar strong associations with outcome measures. The void fraction is the most closely related to the physical porosity of thrombus because it assesses the volume of empty spaces within a material. However, the attenuation increase is a more straightforward measure because it only requires measures in the thrombus itself. It is likely that the 
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This study has several limitations. All patients in this study participated in the MR CLEAN trial, which studied the efficacy of IAT. 8 Consequently, the patient group without IV r-tPA was small, so that this study could not assess the effect of thrombus perviousness on treatment success of IV r-tPA. We plan to perform this study in a population used to evaluate IV r-tPA treatment effect, and evaluate its association of thrombus perviousness. In this study, we considered thrombi as homogeneous and we determined the mean thrombus attenuation ρ, as determined by 3 measured regions of interest in the thrombus. However, it has been shown that composition may vary within the thrombus, 22 such that variations of the attenuation increase may occur within the thrombus. To study this spatial dependence, attenuation measurement of entire segmented thrombus could be used, 17 however, it was not considered in this study.
We used CTA for assessing contrast penetration in intracranial large vessel thrombi. CTA can be regarded as a snapshot in time (which may also vary between institutions or between scanner types) because it images the contrast distribution at a single moment. 23 An intracranial thrombus may limit the hemodynamic flow and result in incomplete filling or even in pseudo-occlusions. 21, 24 Therefore, at the moment of imaging, the contrast may not have fully penetrated the thrombus, resulting in an underestimation of the maximal attenuation increase in CTA. Moreover, in the proposed measure, the radiological timing of the CTA acquisition may also be critical; early phase or delayed phase acquisitions may underestimate the perviousness. To prevent this dependence, we excluded patient with early or late acquisitions. Fortunately, in our data set only 1 patient showed a much delayed arterial phase, and it was therefore excluded. Time-invariant CTA imaging, in which a CTA is generated from computed tomography perfusion acquisitions, 25 as well as a multiphase CTA 26 may be valuables alternative to tackle these problems.
We used measurements averaged ≥4 observers to ensure that differences between NCCT and CTA measurements were not caused by (user dependent) measurement variations. When the trained observers were not able to perform density assessment on a patient (eg, because of a mediocre image quality or difficulty in locating the occlusion), this patient was assessed by an expert observer. Averaging among observers may reduce extreme attenuation values. Of course, combining measurements of multiple observers cannot be performed in clinical practice. This study did not address the effect of increased variation by single measurements. Previous studies 10 showed that the interobserver variation of NCCT-based thrombus attenuation measurement has a SD of ≈±6 HU. Because the dichotomization threshold was larger than this value, it is expected that perviousness classification is insensitive to the number of observers, making it a potentially valuable quantitative characteristic of the thrombus.
Our study describes a new quantitative imaging marker, which is strongly associated with patient outcome and could contribute to an improved AIS patient prognosis. This measure is also associated with FIV and recanalization and may support improved prognosis and treatment selection for patients with AIS. 27, 28 
Conclusions
Combined attenuation measurement of CTA and NCCT revealed a thrombus attenuation increase in CTA in the majority of the thrombi, which is most likely related to thrombus permeability. This increase is strongly associated with improved functional outcome, smaller final infarct volume, and higher recanalization rate. 
SUPPLEMENTAL MATERIAL
Supplemental Method I
Derivation of the void fraction measurement
Void fraction represents the ratio of the void volume, which is filled with blood V Blood , and the total thrombus volume V Thrombus :
The void fraction can be assessed by measuring the attenuation in CT and CTA images. The attenuations measured in a ROI on the thrombus ρ ROIThrombus can be approximated of a linear combination of the attenuation of thrombus material ρ TM and blood ρ Blood :
The void fraction can be determined by combining the attenuation measurements of the CTA and the NCCT scans:
Where ρ CTA TM and ρ NCCT TM are the attenuations of the thrombus material itself on CTA and NCCT respectively. Since this attenuation is considered independent of the imaging modality, as no contrast can flows into plain material, then
ρ CTA Blood and ρ NCCT Blood are the intensities of blood on CTA and NCCT, which can be measured using ROI in the contralateral arteries. Subtracting Equations 3 from 4 results in
This leads to
Overall, the measurement assesses the attenuation increase Δ in the thrombus due to the addition of contrast agent and corrects it with the contrast enhancement of blood Δ c .
